Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.45 |
| ▸ | ARG2 | P78540 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558784 | 0.77 | MEN1 (0.38) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL1915862 | 0.76 | ARG2 (0.47) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL14764832 | 0.76 | ARG1 (0.43) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL14764529 | 0.74 | MEN1 (0.52) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL1916175 | 0.73 | ARG2 (0.53) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL7362369 | 0.71 | ARG1 (0.39) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL25660733 | 0.70 | GGT1 (0.52) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL31688814 | 0.70 | GGT1 (0.52) | ARG1ARG2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL1739397 | 0.69 | ARG1 (0.88) | ARG1ARG2 | |
| SCHEMBL2049448 | 0.68 | CYP1A2 (0.33) | ARG1ARG2ALDH1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | ARG1 1568/4885ARG2 538/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.